Charles River Laboratories International, Inc. (CRL) EV/FCF Ratio: 30.84x
Is Charles River Laboratories International, Inc.’s EV/FCF ratio high or low?
Charles River Laboratories International, Inc.'s EV/FCF ratio of 30.84x is 12% below its 5-year average of 35.23x, around the middle of its 5-year range (15.21x–58.96x).
The EV/FCF ratio for Charles River Laboratories International, Inc. (CRL) is 30.84x as of Wednesday, June 10, 2026. It is above its 12-month average by 45.23% (21.24x).
CRL EV/FCF Ratio Chart
CRL Average EV/FCF Ratio Chart
CRL Current vs Average EV/FCF Ratio Chart
CRL EV/FCF Ratio Metrics
EV/FCF RATIO
30.84x
EV/FCF RATIO AVG TTM
21.24x
EV/FCF RATIO AVG 3Y
29.09x
EV/FCF RATIO AVG 5Y
35.23x
EV/FCF RATIO AVG 10Y
31.58x
EV/FCF RATIO AVG 15Y
27.18x
EV/FCF RATIO AVG 20Y
42.67x
CURRENT VS TTM AVG
+45.23%
CURRENT VS 3Y AVG
+6.03%
CURRENT VS 5Y AVG
-12.46%
CURRENT VS 10Y AVG
-2.34%
CURRENT VS 15Y AVG
+13.48%
CURRENT VS 20Y AVG
-27.72%
CRL Competitors' EV/FCF Ratio
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Charles River Laboratories International, Inc. (CRL) | $9.06B | 30.84x | 21.24x | 29.09x | 35.23x |
| Bio-Rad Laboratories, Inc. (BIO) | $7.89B | 24.48x | 25.09x | 43.47x | 51.10x |
| Baxter International Inc. (BAX) | $10.49B | 25.39x | 68.29x | 51.70x | 47.33x |
| Hims & Hers Health, Inc. (HIMS) | $6.42B | 98.69x | 83.00x | 71.55x | 71.55x |
| Align Technology, Inc. (ALGN) | $12.56B | 16.92x | 17.72x | 29.59x | 38.96x |
| Hologic, Inc. (HOLX) | $16.97B | 17.53x | 16.89x | 18.61x | 15.13x |
| Moderna, Inc. (MRNA) | $18.40B | N/A | 26.90x | 26.23x | 26.23x |
| BioNTech SE (BNTX) | $21.81B | 7.13x | 22.05x | 6.21x | 11.27x |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 31.65x | 33.77x | 33.51x | 38.38x |
| Waters Corporation (WAT) | $23.83B | 133.18x | 43.36x | 43.04x | 41.43x |
Cash Flow Valuation Comparison
EV/FCF
30.8x
P/FCF
23.5x
FCF Yield
4.25%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
- EV/FCF accounts for debt and cash through enterprise value
- P/FCF only considers equity value
- EV/FCF can be compared across companies with different debt levels
- Both measure how the market values cash generation
Charles River Laboratories International, Inc. EV/FCF Ratio Formula & Definition
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Charles River Laboratories International, Inc. EV/FCF Ratio FAQ
- What is the EV/FCF ratio for Charles River Laboratories International, Inc. (CRL)?
- The EV/FCF ratio for CRL stock is 30.84x.
- Is Charles River Laboratories International, Inc.'s EV/FCF ratio high or low?
- Charles River Laboratories International, Inc.'s EV/FCF ratio of 30.84x is 12% below its 5-year average of 35.23x, around the middle of its 5-year range (15.21x–58.96x).
- What is the TTM average EV/FCF ratio for Charles River Laboratories International, Inc. (CRL)?
- The TTM average EV/FCF ratio for CRL stock is 21.24x.
- What is the 3Y average EV/FCF ratio for Charles River Laboratories International, Inc. (CRL)?
- The 3Y average EV/FCF ratio for CRL stock is 29.09x.
- What is the 5Y average EV/FCF ratio for Charles River Laboratories International, Inc. (CRL)?
- The 5Y average EV/FCF ratio for CRL stock is 35.23x.
- What is the 10Y average EV/FCF ratio for Charles River Laboratories International, Inc. (CRL)?
- The 10Y average EV/FCF ratio for CRL stock is 31.58x.
- What is the 15Y average EV/FCF ratio for Charles River Laboratories International, Inc. (CRL)?
- The 15Y average EV/FCF ratio for CRL stock is 27.18x.
- What is the 20Y average EV/FCF ratio for Charles River Laboratories International, Inc. (CRL)?
- The 20Y average EV/FCF ratio for CRL stock is 42.67x.
Charles River Laboratories International, Inc. EV/FCF Ratio History
| DATE | EV/FCF RATIO |
|---|---|
| 2026-06-10 | 30.84x |
| 2026-06-09 | 31.07x |
| 2026-06-08 | 30.64x |
| 2026-06-05 | 30.01x |
| 2026-06-04 | 30.56x |
| 2026-06-03 | 29.82x |
| 2026-06-02 | 29.19x |
| 2026-06-01 | 30.10x |
| 2026-05-29 | 29.93x |
| 2026-05-28 | 30.01x |
| 2026-05-27 | 27.90x |
| 2026-05-26 | 26.93x |
| 2026-05-22 | 27.37x |
| 2026-05-21 | 27.19x |
| 2026-05-20 | 26.84x |
| 2026-05-19 | 26.39x |
| 2026-05-18 | 26.08x |
| 2026-05-15 | 26.19x |
| 2026-05-14 | 27.23x |
| 2026-05-13 | 27.69x |
| 2026-05-12 | 28.42x |
| 2026-05-11 | 28.40x |
| 2026-05-08 | 29.54x |
| 2026-05-07 | 30.05x |
| 2026-05-06 | 22.75x |
| 2026-05-05 | 23.10x |
| 2026-05-04 | 21.86x |
| 2026-05-01 | 21.24x |
| 2026-04-30 | 21.35x |
| 2026-04-29 | 21.05x |
| 2026-04-28 | 21.33x |
| 2026-04-27 | 21.75x |
| 2026-04-24 | 21.62x |
| 2026-04-23 | 21.42x |
| 2026-04-22 | 23.04x |
| 2026-04-21 | 22.88x |
| 2026-04-20 | 23.11x |
| 2026-04-17 | 22.95x |
| 2026-04-16 | 22.30x |
| 2026-04-15 | 22.64x |
| 2026-04-14 | 22.52x |
| 2026-04-13 | 22.43x |
| 2026-04-10 | 22.17x |
| 2026-04-09 | 22.16x |
| 2026-04-08 | 22.12x |
| 2026-04-07 | 21.59x |
| 2026-04-06 | 21.47x |
| 2026-04-02 | 22.01x |
| 2026-04-01 | 22.10x |
| 2026-03-31 | 21.87x |
| 2026-03-30 | 20.66x |
| 2026-03-27 | 20.61x |
| 2026-03-26 | 21.17x |
| 2026-03-25 | 21.25x |
| 2026-03-24 | 20.61x |
| 2026-03-23 | 20.50x |
| 2026-03-20 | 20.08x |
| 2026-03-19 | 20.03x |
| 2026-03-18 | 20.41x |
| 2026-03-17 | 20.09x |
| 2026-03-16 | 19.93x |
| 2026-03-13 | 20.26x |
| 2026-03-12 | 19.99x |
| 2026-03-11 | 21.53x |
| 2026-03-10 | 21.39x |
| 2026-03-09 | 22.30x |
| 2026-03-06 | 22.06x |
| 2026-03-05 | 22.71x |
| 2026-03-04 | 22.55x |
| 2026-03-03 | 22.18x |
| 2026-03-02 | 22.45x |
| 2026-02-27 | 22.44x |
| 2026-02-26 | 22.15x |
| 2026-02-25 | 21.41x |
| 2026-02-24 | 21.26x |
| 2026-02-23 | 21.02x |
| 2026-02-20 | 21.53x |
| 2026-02-19 | 21.09x |
| 2026-02-18 | 20.50x |
| 2026-02-17 | 18.87x |
| 2026-02-13 | 19.13x |
| 2026-02-12 | 18.89x |
| 2026-02-11 | 19.55x |
| 2026-02-10 | 20.93x |
| 2026-02-09 | 21.34x |
| 2026-02-06 | 21.66x |
| 2026-02-05 | 21.16x |
| 2026-02-04 | 22.79x |
| 2026-02-03 | 22.77x |
| 2026-02-02 | 23.84x |
| 2026-01-30 | 23.59x |
| 2026-01-29 | 23.70x |
| 2026-01-28 | 24.17x |
| 2026-01-27 | 24.42x |
| 2026-01-26 | 24.67x |
| 2026-01-23 | 24.42x |
| 2026-01-22 | 24.82x |
| 2026-01-21 | 25.07x |
| 2026-01-20 | 24.29x |
| 2026-01-16 | 24.43x |
| 2026-01-15 | 24.77x |
| 2026-01-14 | 24.13x |
| 2026-01-13 | 24.37x |
| 2026-01-12 | 24.35x |
| 2026-01-09 | 24.54x |
| 2026-01-08 | 24.05x |
| 2026-01-07 | 24.16x |
| 2026-01-06 | 24.10x |
| 2026-01-05 | 23.40x |
| 2026-01-02 | 22.86x |
| 2025-12-31 | 22.59x |
| 2025-12-30 | 22.82x |
| 2025-12-29 | 22.93x |
| 2025-12-26 | 22.97x |
| 2025-12-24 | 22.93x |
| 2025-12-23 | 22.90x |
| 2025-12-22 | 22.91x |
| 2025-12-19 | 22.37x |
| 2025-12-18 | 22.08x |
| 2025-12-17 | 22.27x |
| 2025-12-16 | 22.21x |
| 2025-12-15 | 22.47x |
| 2025-12-12 | 22.01x |
| 2025-12-11 | 22.13x |
| 2025-12-10 | 22.17x |
| 2025-12-09 | 21.37x |
| 2025-12-08 | 21.47x |
| 2025-12-05 | 21.21x |
| 2025-12-04 | 21.19x |
| 2025-12-03 | 21.25x |
| 2025-12-02 | 20.35x |
| 2025-12-01 | 20.47x |
| 2025-11-28 | 20.65x |
| 2025-11-26 | 20.73x |
| 2025-11-25 | 20.64x |
| 2025-11-24 | 19.95x |
| 2025-11-21 | 19.70x |
| 2025-11-20 | 19.19x |
| 2025-11-19 | 19.15x |
| 2025-11-18 | 19.23x |
| 2025-11-17 | 19.25x |
| 2025-11-14 | 19.71x |
| 2025-11-13 | 19.84x |
| 2025-11-12 | 20.05x |
| 2025-11-11 | 20.23x |
| 2025-11-10 | 19.82x |
| 2025-11-07 | 19.74x |
| 2025-11-06 | 19.99x |
| 2025-11-05 | 19.70x |
| 2025-11-04 | 19.66x |
| 2025-11-03 | 19.75x |
| 2025-10-31 | 19.85x |
| 2025-10-30 | 19.77x |
| 2025-10-29 | 19.86x |
| 2025-10-28 | 20.52x |
| 2025-10-27 | 21.15x |
| 2025-10-24 | 21.30x |
| 2025-10-23 | 20.78x |
| 2025-10-22 | 20.44x |
| 2025-10-21 | 20.55x |
| 2025-10-20 | 20.20x |
| 2025-10-17 | 19.72x |
| 2025-10-16 | 19.41x |
| 2025-10-15 | 19.05x |
| 2025-10-14 | 19.00x |
| 2025-10-13 | 19.05x |
| 2025-10-10 | 18.74x |
| 2025-10-09 | 19.17x |
| 2025-10-08 | 19.29x |
| 2025-10-07 | 19.00x |
| 2025-10-06 | 19.41x |
| 2025-10-03 | 19.62x |
| 2025-10-02 | 19.45x |
| 2025-10-01 | 19.03x |
| 2025-09-30 | 17.84x |
| 2025-09-29 | 17.03x |
| 2025-09-26 | 17.16x |
| 2025-09-25 | 16.91x |
| 2025-09-24 | 17.24x |
| 2025-09-23 | 17.31x |
| 2025-09-22 | 17.62x |
| 2025-09-19 | 17.75x |
| 2025-09-18 | 17.88x |
| 2025-09-17 | 17.52x |
| 2025-09-16 | 17.42x |
| 2025-09-15 | 17.48x |
| 2025-09-12 | 17.53x |
| 2025-09-11 | 18.12x |
| 2025-09-10 | 17.57x |
| 2025-09-09 | 17.92x |
| 2025-09-08 | 18.31x |
| 2025-09-05 | 18.48x |
| 2025-09-04 | 18.34x |
| 2025-09-03 | 18.34x |
| 2025-09-02 | 18.25x |
| 2025-08-29 | 18.42x |
| 2025-08-28 | 18.41x |
| 2025-08-27 | 18.38x |
| 2025-08-26 | 18.46x |
| 2025-08-25 | 18.49x |
| 2025-08-22 | 18.30x |
| 2025-08-21 | 17.67x |
| 2025-08-20 | 18.10x |
| 2025-08-19 | 18.01x |
| 2025-08-18 | 17.88x |
| 2025-08-15 | 17.86x |
| 2025-08-14 | 17.78x |
| 2025-08-13 | 17.71x |
| 2025-08-12 | 17.52x |
| 2025-08-11 | 17.20x |
| 2025-08-08 | 17.18x |
| 2025-08-07 | 17.27x |
| 2025-08-06 | 17.32x |
| 2025-08-05 | 20.02x |
| 2025-08-04 | 20.05x |
| 2025-08-01 | 19.96x |
| 2025-07-31 | 20.21x |
| 2025-07-30 | 20.80x |
| 2025-07-29 | 21.01x |
| 2025-07-28 | 21.05x |
| 2025-07-25 | 20.87x |
| 2025-07-24 | 20.88x |
| 2025-07-23 | 20.06x |
| 2025-07-22 | 19.64x |
| 2025-07-21 | 18.42x |
| 2025-07-18 | 18.84x |
| 2025-07-17 | 19.04x |
| 2025-07-16 | 18.88x |
| 2025-07-15 | 18.84x |
| 2025-07-14 | 19.16x |
| 2025-07-11 | 19.29x |
| 2025-07-10 | 19.67x |
| 2025-07-09 | 19.25x |
| 2025-07-08 | 19.19x |
| 2025-07-07 | 18.79x |
| 2025-07-03 | 19.08x |
| 2025-07-02 | 19.11x |
| 2025-07-01 | 18.83x |
| 2025-06-30 | 18.59x |
| 2025-06-27 | 18.44x |
| 2025-06-26 | 18.58x |
| 2025-06-25 | 18.46x |
| 2025-06-24 | 18.29x |
| 2025-06-23 | 18.20x |
| 2025-06-20 | 18.21x |
| 2025-06-18 | 18.01x |
| 2025-06-17 | 17.99x |
| 2025-06-16 | 18.53x |
| 2025-06-13 | 18.39x |
| 2025-06-12 | 18.61x |
| 2025-06-11 | 18.54x |
| 2025-06-10 | 18.53x |
| 2025-06-09 | 18.21x |
| 2025-06-06 | 17.96x |
| 2025-06-05 | 17.64x |
| 2025-06-04 | 17.82x |
| 2025-06-03 | 17.40x |
| 2025-06-02 | 17.09x |
| 2025-05-30 | 17.14x |
| 2025-05-29 | 17.33x |
Showing the most recent 260 of 4,916 data points. The chart above shows the full history.
Related Metrics
About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- James C. Foster